Yi-Ling Liu

Title: Yi-Ling Liu: Innovator in Cancer Immunotherapy

Introduction

Yi-Ling Liu is a prominent inventor based in Miaoli County, Taiwan. He has made significant contributions to the field of cancer immunotherapy, focusing on innovative approaches to enhance treatment efficacy. With a total of 2 patents, Liu's work is paving the way for advancements in cancer treatment.

Latest Patents

Liu's latest patents include groundbreaking inventions that combine CpG-oligodeoxynucleotide compounds with immune modulators for cancer immunotherapy. The first patent discloses a combinational therapy aimed at enhancing the efficacy of immune checkpoint blockade for tumors characterized by an immune suppressive microenvironment. This innovative therapy utilizes immune checkpoint inhibitors alongside CpG-oligodeoxynucleotides to treat cancer effectively. The second patent presents a CpG-oligodeoxynucleotide (CpG-ODN) designed to induce a TLR9 activated immune response, a TLR21 activated immune response, or a combination of both in a host. This CpG-ODN includes specific sequences that are crucial for inducing an immune response, along with an immunogenic composition and a method for its application.

Career Highlights

Yi-Ling Liu is affiliated with the National Health Research Institutes, where he conducts research and develops innovative solutions for cancer treatment. His work is characterized by a commitment to improving patient outcomes through scientific advancements.

Collaborations

Liu collaborates with esteemed colleagues, including Tsung-Hsien Chuang and Da-Wei Yeh, to further enhance the impact of his research in the field of immunotherapy.

Conclusion

Yi-Ling Liu's contributions to cancer immunotherapy through his innovative patents demonstrate his dedication to advancing medical science. His work not only highlights the importance of collaboration in research but also showcases the potential for new therapies to improve cancer treatment outcomes.